Plus: Eli Lilly’s obesity pill gets approval, and will take on a rival from Novo Nordisk in the booming GLP-1 drug market. And the Trump Administration is expected to overhaul steel and aluminum tariffs. Luke Vargas hosts.
Sign up for WSJ’s free What’s News newsletter.
Learn more about your ad choices. Visit megaphone.fm/adchoices